Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 63

2 391 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 391
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 391 trials in Milan

Open in trial search

Bladder transitional cell carcinoma

Recruiting

Study of Cabozantinib and Durvalumab for Patients with Advanced Bladder Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Colorectal cancer+5

Recruiting

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Cholangiocarcinoma

Recruiting

Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Transthera Sciences (Nanjing) Inc.

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of BGB-11417 and Azacitidine for Patients with Myeloid Malignancies (AML, MDS, MDS/MPN)

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:BeOne Medicines AG

Fallopian tube cancer+5

Recruiting

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Systemic scleroderma+1

Recruiting

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cervix carcinoma

Recruiting

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Critical illness

Recruiting

Study on Preventing Cardiovascular Collapse in Critically Ill Adults Using Noradrenaline Tartrate During Tracheal Intubation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Noradrenaline Tartrate
  • Sponsor:Universita' Degli Studi Di Torino

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Non-small cell lung cancer metastatic

Recruiting

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.